

ER

OBSAH

NOVINKY Z LETOŠNÍHO NEJVÝZNAMNĚJŠÍHO SETKÁNÍ HEMATOLOGŮ

LYMFOMY

CÍLENÁ TERAPIE A LÉČEBNÉ REŽIMY U CHRONICKÉ LYMFOCYTÁRNÍ LEUKEMIE A MALIGNÍCH LYMFOMŮ LUKÁŠ SMOLEJ	str. 5
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL	str. 9
THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL	str. 11
FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA	str. 13
PET AFTER 2 CYCLES OF ABVD IN PATIENTS WITH EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA TREATED WITHIN THE PHASE 3 GHS6 HD16 STUDY	str. 15
REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM	str. 16
BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH BCELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCPALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS	str. 17

AKUTNÍ MYELOIDNÍ LEUKEMIE

CO JE NOVÉHO V LÉČBĚ AML? ZUZANA ŠUSTKOVÁ	str. 20
DECIPHERING THE ROLE OF RUNX1 ISOFORMS IN THE DEVELOPMENT OF TRANSIENT ABNORMAL MYELOPOIESIS	str. 26
THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML	str. 28
PEGCRISANTASPASE AND VENETOCLAX COMBINATION IS HIGHLY EFFECTIVE AGAINST ACUTE MYELOID LEUKEMIA (AML), MECHANISTICALLY DRIVEN SYNERGISM BETWEEN GLUTAMINE DEPLETION AND BCL-2 INHIBITION	str. 30

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS str. 32

SAFETY AND CLINICAL ACTIVITY OF AMV564, A CD33/CD3 T-CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML): UPDATED RESULTS FROM THE PHASE 1 FIRST-IN-HUMAN TRIAL str. 33

IMUNITNÍ MYELOPROLIFERATIVNÍ NEOPLAZIE

NOVINKY Z KONGRESU: MYELOPROLIFERATIVNA NEOPLÁZIA
ANTÓNIA HATALOVÁ str. 35

EARLY SPLEEN RESPONSE IS A GOOD PROGNOSTIC FACTOR OF RUXOLINIB OUTCOME IN PATIENTS WITH MYELOFIBROSIS str. 39

SURVIVAL OUTCOMES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: A POPULATION-BASED COHORT STUDY IN SWEDEN AND NORWAY str. 40

SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB < 10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL str. 42

IMUNITNÍ TROMBOCYTOPENIE

NOVINKY V DIAGNOSTICE A LÉČBĚ IMUNITNÍ TROMBOCYTOPENIE
LIBOR ČERVINEK str. 43

ANTICOAGULANT THERAPY IN THROMBOCYTOPENIC PATIENTS WITH BLOOD CANCER AND CATHETER-RELATED VTE: RESULTS FROM A DELPHI CONSENSUS ON PLATELETS COUNT BELOW $50 \times 10^9/L$ str. 49

ADULT ONSET HEREDITARY THROMBOTIC THROMBOCYTOPENIC PURPURA WITH A NOVEL ADAMTS13 MUTATION str. 50

EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AMONG THE ADULT POPULATION OF THE RUSSIAN FEDERATION str. 51

NOVEL ADAMTS13 MUTATIONS IN A PATIENT OF INHERITED THROMBOTIC THROMBOCYTOPENIC PURPURA str. 52

TIRÁŽ

Nakladatelství a vydavatelství We Make Media, s. r. o. | Jednatelka: MUDr. Ivana Kaderková
Adresa: Italská 24, 120 00 Praha 2, Česká republika | Tel.: +420 778 476 475 | E-mail: info@wemakemedia.cz
www.wemakemedia.cz

Odpovědné redaktorky: PhDr. Jana Vytlačilová, Veronika Lazarová | Jazykové korektorky: PhDr. Hana Kaiserová,
Mgr. Simona Smithová, Mgr. Anetta Letková | Zlom a grafická úprava: We Make Media, s. r. o.
ISBN: 978-80-87339-55-8 | Vyšlo: říjen 2019

Jakékoliv kopírování a šíření celého obsahu nebo jeho částí, a to ať v tištěné, nebo v elektronické formě, je bez souhlasu vydavatelství zakázáno.

Vychází 1x ročně | 3. ročník | V publikaci byly s povolením Evropské hematologické asociace použité texty a fotografie ze zdroje: <https://www.ehaweb.org/>. All rights reserved. © 2019 European Hematology Association.